CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 mAbs, have brought unprecedented and lasting clinical benefits for NSCLC patients, but the response rate for patients with driver gene mutations is still relatively low [4].